 |
市场调查报告书
商品编码
1672738
遗传性血管性水肿市场按类型、药物类别、给药途径、分销管道和地区划分Hereditary Angioedema Market By Type, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
2025 年全球遗传性血管性水肿市场规模估计为 31.3 亿美元，预计到 2032 年将达到 59.6 亿美元，2025 年至 2032 年的复合年增长率为 9.6%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | 2024 | 2025 年市场规模 | 31.3亿美元 |
| 效能资料 | 从 2020 年到 2024 年 | 预测期 | 2025 至 2032 年 |
| 预测期：2025-2032年复合年增长率： | 9.60％ | 2032 年价值预测 | 59.6亿美元 |
遗传性血管性水肿是一种罕见的遗传性疾病，其特征是復发性严重的皮下或黏膜下水肿。症状包括手、脚、四肢、脸部、肠道和呼吸道肿胀。这些发作是由于 C1 抑制剂水平或功能下降引起的，C1 抑制剂是一种控制补体和纤溶系统某些部分的血清蛋白。患有遗传性血管性水肿的患者平均每四周至少会出现一次水肿，通常需要医疗干预来控制症状。该疾病在全球范围内的流行率不断上升以及对可用治疗方案的认识不断提高，可能会推动遗传性血管性水肿市场的成长。
市场动态
对替代治疗方法的研究不断增加、全球 HAE 盛行率不断上升、 FDA认证核可药的可用性以及对该疾病的认识不断提高，可能会推动遗传性血管性水肿市场的成长。然而，HAE 治疗的高成本和新兴国家的低认知度可能会阻碍市场的成长。皮下C1-INH产品和口服疗法的开发将为市场相关人员提供新的机会。
本研究的主要特点
本报告对全球遗传性血管性水肿市场进行了详细分析，并给出了预测期（2025-2032）的市场规模和年复合成长率（CAGR%），假设 2024 年为基准年。
它还强调了各个领域的潜在商机并说明了该市场的有吸引力的投资提案矩阵。
它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
全球遗传性血管性水肿市场的关键参与者根据公司亮点、产品系列、关键亮点、财务表现和策略等参数进行分析。
主要公司包括 CSL Behring、赛诺菲、武田药品工业株式会社、Attune Pharmaceuticals、Arrowhead Pharmaceuticals, Inc.、Adverum Biotechnologies, Inc.、KalVista Pharmaceuticals 和 CENTOGENE NV。
本报告的见解将使负责人和企业经营团队能够就未来产品发布、高端市场策略、市场扩张和行销策略做出明智的决策。
全球遗传性血管性水肿市场报告涉及该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员将透过用于分析全球遗传性血管性水肿市场的各种策略矩阵更轻鬆地做出决策。
目录
第一章 调查目的与前提条件
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
- 遗传性血管性水肿市场（按类型）
- 遗传性血管性水肿市场（依药物类别）
- 遗传性血管性水肿市场（依给药途径）
- 遗传性血管性水肿市场，依分销管道划分
- 遗传性血管性水肿市场（按地区）
第三章市场动态、法规与趋势分析
- 市场动态
- 影响分析
- 主要亮点
- 监管情景
- 产品发布/核准
- PEST分析
- PORTER 分析
- 併购情景
- 流行病学
- 管道分析
4. 遗传性血管性水肿市场，依类型，2020-2032 年（十亿美元）
- 2025 年及 2032 年市场占有率分析（%）
- 与前一年同期比较成长分析
- 细分趋势
- 遗传性血管性水肿 I 型
- 市场规模及预测，与前一年同期比较（十亿美元）
- 遗传性血管性水肿 II 型
- 市场规模及预测，与前一年同期比较（十亿美元）
5. 遗传性血管性水肿市场，依药物类别，2020-2032 年（十亿美元）
- 2025 年及 2032 年市场占有率分析（%）
- 与前一年同期比较成长分析
- 细分趋势
- C1 酯酶抑制剂
- 市场规模及预测，与前一年同期比较（十亿美元）
- 激肽释放酶抑制剂
- 市场规模及预测，与前一年同期比较（十亿美元）
- 缓激肽受体
- 市场规模及预测，与前一年同期比较（十亿美元）
- 雄激素减弱
- 市场规模及预测，与前一年同期比较（十亿美元）
- 其他的
- 市场规模及预测，与前一年同期比较（十亿美元）
6. 遗传性血管性水肿市场，依给药途径，2020-2032 年（十亿美元）
- 2025 年及 2032 年市场占有率分析（%）
- 与前一年同期比较成长分析
- 细分趋势
- 皮下
- 市场规模及预测，与前一年同期比较（十亿美元）
- 静脉
- 市场规模及预测，与前一年同期比较（十亿美元）
- 口服
- 市场规模及预测，与前一年同期比较（十亿美元）
7. 遗传性血管性水肿市场，按分销管道，2020-2032 年（十亿美元）
- 2025 年及 2032 年市场占有率分析（%）
- 与前一年同期比较成长分析
- 细分趋势
- 医院药房
- 市场规模及预测，与前一年同期比较（十亿美元）
- 零售药局
- 市场规模及预测，与前一年同期比较（十亿美元）
- 网路药局
- 市场规模及预测，与前一年同期比较（十亿美元）
8. 遗传性血管性水肿市场，按地区，2020-2032 年（十亿美元）
- 2025 年、2028 年、2032 年市场占有率(%) 分析（单位：十亿美元）
- 市场与前一年同期比较分析（%），（十亿美元）
- 区域趋势
- 北美洲
- 市场规模及预测（按类型划分）（十亿美元）
- 市场规模及预测（按药品类别划分）（十亿美元）
- 按给药途径分類的市场规模和预测（十亿美元）
- 按分销管道分類的市场规模和预测（十亿美元）
- 各国市场规模及预测（十亿美元）
- 拉丁美洲
- 市场规模及预测（按类型划分）（十亿美元）
- 市场规模及预测（按药品类别划分）（十亿美元）
- 按给药途径分類的市场规模和预测（十亿美元）
- 按分销管道分類的市场规模和预测（十亿美元）
- 各国市场规模及预测（十亿美元）
- 欧洲
- 市场规模及预测（按类型划分）（十亿美元）
- 市场规模及预测（按药品类别划分）（十亿美元）
- 按给药途径分類的市场规模和预测（十亿美元）
- 按分销管道分類的市场规模和预测（十亿美元）
- 各国市场规模及预测（十亿美元）
- 亚太地区
- 市场规模及预测（按类型划分）（十亿美元）
- 市场规模及预测（按药品类别划分）（十亿美元）
- 按给药途径分類的市场规模和预测（十亿美元）
- 按分销管道分類的市场规模和预测（十亿美元）
- 各国市场规模及预测（十亿美元）
- 中东
- 市场规模及预测（按类型划分）（十亿美元）
- 市场规模及预测（按药品类别划分）（十亿美元）
- 按给药途径分類的市场规模和预测（十亿美元）
- 按分销管道分類的市场规模和预测（十亿美元）
- 各国市场规模及预测（十亿美元）
- 非洲
- 市场规模及预测（按类型划分）（十亿美元）
- 市场规模及预测（按药品类别划分）（十亿美元）
- 按给药途径分類的市场规模和预测（十亿美元）
- 按分销管道分類的市场规模和预测（十亿美元）
- 各国家/地区市场规模及预测（十亿美元）
第九章 竞争格局
- CSL Behring
- Sanofi
- Takeda Pharmaceutical Company Limited
- Orchard Therapeutics plc.
- Pharming Group NV
- BioCryst Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Attune Pharmaceuticals
- Arrowhead Pharmaceuticals, Inc.
- Adverum Biotechnologies, Inc.
- KalVista Pharmaceuticals
- CENTOGENE NV
第 10 章分析师建议
第 11 章 参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
Global Hereditary Angioedema Market is estimated to be valued at USD 3.13 Bn in 2025 and is expected to reach USD 5.96 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.6% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 3.13 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 9.60% | 2032 Value Projection: | USD 5.96 Bn |
Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of intense subcutaneous or submucosal edema. Symptoms include episodes of swelling in the hands, feet, limbs, face, intestinal tract and airway. The episodes are caused by decreased levels or functioning of C1 inhibitor, which is a serum protein responsible for regulating certain parts of the complement and fibrinolytic systems. Patients with hereditary angioedema experience episodes of edema at least once every 4 weeks on average and commonly require medical intervention for symptom management. Increasing prevalence of disease globally and rising awareness about available treatment options can drive the hereditary angioedema market growth.
Market Dynamics
Increasing research into treatment alternatives, rising prevalence of HAE globally, availability of FDA approved drugs and growing awareness about the disease can drive the hereditary angioedema market growth. However, high costs associated with HAE therapies and lack of awareness in developing countries can hamper the market growth. Development of subcutaneous C1-INH products and oral treatments offers new opportunities for the market players.
Key features of the study
This report provides in-depth analysis of the global hereditary angioedema market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hereditary angioedema market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include CSL Behring, Sanofi, Takeda Pharmaceutical Company Limited, Orchard Therapeutics plc., Pharming Group N.V., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, and CENTOGENE N.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global hereditary angioedema market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hereditary angioedema market
Market Segmentation
- By Type Insights (Revenue, USD Bn, 2019 - 2032)
- Hereditary Angioedema Type I
- Hereditary Angioedema Type II
- By Drug Class Insights (Revenue, USD Bn, 2019 - 2032)
- C1 Esterase Inhibitor
- Kallikrein Inhibitor
- Bradykinin Receptor
- Attenuated Androgens
- Others
- By Route of Administration Insights (Revenue, USD Bn, 2019 - 2032)
- Subcutaneous
- Intravenous
- Oral
- By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights (Revenue, USD Bn, 2019 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- CSL Behring
- Sanofi
- Takeda Pharmaceutical Company Limited
- Orchard Therapeutics plc.
- Pharming Group N.V.
- BioCryst Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Attune Pharmaceuticals
- Arrowhead Pharmaceuticals, Inc.
- Adverum Biotechnologies, Inc.
- KalVista Pharmaceuticals
- CENTOGENE N.V.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Hereditary Angioedema Market, By Type
- Hereditary Angioedema Market, By Drug Class
- Hereditary Angioedema Market, By Route of Administration
- Hereditary Angioedema Market, By Distribution Channel
- Hereditary Angioedema Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Epidemiology
- Pipeline Analysis
4. Hereditary Angioedema Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hereditary Angioedema Type I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hereditary Angioedema Type II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Hereditary Angioedema Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- C1 Esterase Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Kallikrein Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bradykinin Receptor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Attenuated Androgens
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Hereditary Angioedema Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Hereditary Angioedema Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Hereditary Angioedema Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- CSL Behring
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Orchard Therapeutics plc.
- Pharming Group N.V.
- BioCryst Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Attune Pharmaceuticals
- Arrowhead Pharmaceuticals, Inc.
- Adverum Biotechnologies, Inc.
- KalVista Pharmaceuticals
- CENTOGENE N.V.
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
遗传性血管性水肿治疗市场 - 全球产业规模、份额、趋势、机会和预测，按药物类别、配销通路、应用、地区和竞争细分，2020-2030 年预测
遗传性血管性水肿治疗市场规模、份额、成长分析、按治疗方法、按给药途径、按分销管道、按最终用途、按地区 - 行业预测，2025-2032 年
遗传性血管水肿治疗药物市场：依药物类别、治疗类型、给药途径分类 - 2025-2030 年全球预测
遗传性血管水肿 (HAE) 治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032
遗传性血管水肿治疗药物市场规模、份额和趋势分析报告：2023-2030 年按治疗、给药途径、最终用途、地区和细分市场分類的趋势